

**A - ORIGINAL ARTICLES IN PEER REVIEWED JOURNALS**

(Alphabetisch nach Erstautor sortiert)

ABBOTT AL, ADELMAN MA, ALEXANDROV AV, BARBER PA, BARNETT HJ, BEARD J, BELL P, BJORCK M, BLACKER D, **BONATI LH**, BROWN MM, BUCKLEY CJ, CAMBRIA RP, CASTALDO JE, COMEROTA AJ, CONNOLLY ES, JR., DALMAN RL, DAVIES AH, ECKSTEIN HH, FARUQI R, FEASBY TE, FRAEDRICH G, GLOVICZKI P, HANKEY GJ, HARBAUGH RE, HELDENBERG E, HENNERICI MG, HILL MD, KLEINIG TJ, MIKHAILIDIS DP, MOORE WS, NAYLOR R, NICOLAIDES A, PARASKEVAS KI, PELZ DM, PRICHARD JW, PURDIE G, RICCO JB, RINGLEB PA, RILES T, ROTHWELL PM, SANDERCOCK P, SILLESEN H, SPENCE JD, SPINELLI F, STURM J, TAN A, THAPAR A, VEITH FJ, WIJERATNE T, ZHOU W.

Why calls for more routine carotid stenting are currently inappropriate: an international, multi-specialty, expert review and position statement.

Stroke 2013; 44(4):1186-90. IF: 6.16

**ACHTNICHTS L**, GONEN O, RIGOTTI DJ, BABB JS, **NAEGELIN Y**, **PENNER IK**, **BENDFELDT K**, **HIRSCH J**, **AMANN M**, **KAPPOS L**, **GASS A**.

Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration.

Eur J Radiol. 82 (2013) e848– e852 IF: 2.512

ALTINBAS A, VAN ZANDVOORT MJ, VAN DEN BERG E, ALGRA A, DE BORST GJ, HENDRIKSE J, NEDERKOORN PJ, **BONATI LH**, BROWN MM, KAPPELLE LJ, VAN DER WORP HB.

The effect of white matter lesions on cognition after carotid revascularization.

J Neurol Sci 2013; 334(1-2):77-82. IF: 2.24

AUER-GRUMBACH M, BODE H, PIEBER TR, SCHABHÜTTL M, **FISCHER D**, SEIDL R, GRAF E, WIELAND T, SCHUH R, VACARIU G, GRILL F, TIMMERMAN V, STROM TM, HORNEMANN T  
Mutations at Ser331 in the HSN type I gene SPTLC1 are associated with a distinct syndromic phenotype.

Eur J Med Genet. 2013; 56(5): 266–269. IF: 1.685

AXER H, **GRIMM A**, PORZELIUS C, TESCHNER U, SCHUMACHER U, WITTE OW, BRUNKHORST FM.

Impairment of small somatic and autonomic nerve fibres in intensive care unit patients with severe sepsis and critical illness polyneuropathy -- a single center controlled observational study.

BMC Neurol. 2013; 13(1):159. IF: 2.564

BAR-OR A, GOLD R, **KAPPOS L**, ARNOLD DL, GIOVANNONI G, SELMAJ K, O'GORMAN J, STEPHAN M, DAWSON KT.

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.

J Neurol. 2013; 260(9): 2297-305. IF: 3.578

BÉJOT Y, ABOA-BOULÉ C, DEBETTE S, PEZZINI A, TATLISUMAK T, **ENGELTER S**, GROND-GINSBACH C, TOUZÉ E, SESSA M, METSO T, METSO A, KLOSS M, CASO V, DALLONGEVILLE J, **LYRER P**, LEYS D, GIROUD M, PANDOLFO M, ABBOUD S for the CADISP Group.

Characteristics and outcomes of patients with multiple cervical artery dissection.

Stroke. 2013 Dec 10. [Epub ahead of print] IF: 6.16

**BONATI LH**, EDERLE J, DOBSON J, **ENGELTER S**, FEATHERSTONE RL, GAINES PA, BEARD JD, VENABLES GS, MARKUS HS, CLIFTON A, SANDERCOCK P, BROWN MM; CAVATAS Investigators.

Length of carotid stenosis predicts peri-procedural stroke or death and restenosis in patients randomized to endovascular treatment or endarterectomy.

Int J Stroke. 2013 Jul 29. [Epub ahead of print] IF: 2.38

BRODERICK JP, PALESCH YY, DEMCHUK AM, YEATTS SD, KHATRI P, HILL MD, JAUCH EC, JOVIN TG, YAN B, SILVER FL, VON KUMMER R, MOLINA CA, DEMAERSCHALK BM, BUDZIK R, CLARK WM, ZAIDAT OO, MALISCH TW, GOYAL M, SCHONEWILLE WJ, MAZIGHI M, **BUROW A**, **LYRER P**, NEDERKOORN PJ, BROWN MM, SZTAJZEL R, **ENGELTER S**, **BONATI LH**.

Echographic risk index and cerebral ischemic brain lesions in patients randomized to stenting versus endarterectomy for symptomatic carotid artery stenosis.

Ultraschall Med. 2013 Oct 18. [Epub ahead of print] IF: 4.12.

CALVET D, MAS JL, ALGRA A, BECQUEMIN JP, **BONATI LH**, DOBSON J, FRAEDRICH G, JANSEN O, MALI WP, RINGLEB PA, CHATELLIER G, BROWN MM.

Carotid stenting: Is there an operator effect? A pooled analysis from the carotid stenting trialists' collaboration.

Stroke 2013 December 17. [Epub ahead of print] IF: 6.16

**CASTETS P**, LIN S, RION N, **DI FULVIO S**, ROMANINO K, GURIDI M, FRANK S, TINTIGNAC LA, **SINNREICH M**, RÜEGG MA.

Sustained activation of mTORC1 in skeletal muscle inhibits constitutive and starvation-induced autophagy and causes a severe, late-onset myopathy.

Cell Metab. 2013; 17(5):731-44. IF: 14.619

CEREDA C, ZECCA C, MAZZUCHELLI L, VALCI L, STAEDLER C, BASSETTI C, **GOBBI C**.  
Tumefactive demyelinating lesions during etanercept treatment requiring decompressive hemicraniectomy.

Mult Scler, 2013; 19(6):820-823 IF: 4.472

CLAVAGUERA F, AKATSU H, FRASER G, CROWTHER RA, FRANK S, HENCH J, PROBST A, **WINKLER DT**, REICHWALD J, STAUFENBIEL M, GHETTI B, GOEDERT M, TOLNAY M.

Brain homogenates from human tauopathies induce tau inclusions in mouse brain.

Proc Natl Acad Sci U S A. 2013; 110(23):9535-40. IF: 9.73

CORPORAAL SH\*, **GENSICKE H\***, **KUHLE J**, **KAPPOS L**, ALLUM JH, **YALDIZLI O** (\*equally contributing)

Balance control in multiple sclerosis: Correlations of trunk sway during stance and gait tests with disease severity

Gait Posture 2013, 37(1), 55-60 IF: 1.969

**DE MARCHIS GM**, KATAN M, WECK A, FLURI F, FOERCH C, FINDLING O, SCHUETZ P, BUHL D, EL-KOUSSY M, **GENSICKE H**, SEILER M, MORGENTHALER N, MATTLE HP, MUELLER B, CHRIST-CRAIN M, ARNOLD M.

Copeptin adds prognostic information after ischemic stroke: results from the CoRisk study.

Neurology 2013; 80:1278-86. IF: 8.249

DISANTO G, KJETIL SANDVE G, RICIGLIANO VA, PAKPOOR J, BERLANGA-TAYLOR AJ, HANDEL AE, **KUHLE J**, HOLDEN L, WATSON CT, GIOVANNONI G, HANDUNNETTHI L, RAMAGOPALAN SV

DNase hypersensitive sites and association with multiple sclerosis

Human Molecular Genetics 2013, [epub ahead of print] IF: 7.692

EDAN G\*, **KAPPOS L\***, MONTALBÁN X, POLMAN CH, FREEDMAN MS, HARTUNG HP, MILLER D, BARKHOF F, HERRMANN J, LANIUS V, STEMPEL B, POHL C, SANDBRINK R, PLEIMES D; for the BENEFIT Study Group. (\* Equal contribution)  
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.  
J Neurol Neurosurg Psychiatry. 2013 Nov 11. [Epub ahead of print] IF: 4.924

EDERLE J, DAVAGNANAM I, VAN DER WORP HB, VENABLES GS, **LYRER P**, FEATHERSTONE RL, BROWN MM, JÄGER HR; ICSS investigators.  
Effect of white-matter lesions on the risk of periprocedural stroke after carotid artery stenting versus endarterectomy in the International Carotid Stenting Study (ICSS): a prespecified analysis of data from a randomised trial.  
Lancet Neurol. 2013; 12(9):866-72. IF: 39.06

### **ENGELTER S**

Safety in pharmacological enhancement of stroke rehabilitation.  
Eur J Phys Rehabil Med. Eur J Phys Rehabil Med. 2013; 49(2):261-7. IF: 1.4

**ENGELTER S**, GROND-GINSBACH C, METSO TM, METSO AJ, KLOSS M, DEBETTE S, LEYS D, GRAU A, DALLONGEVILLE J, BODENANT M, SAMSON Y, CASO V, PEZZINI A, **BONATI LH**, THIJS V, **GENSICKE H**, MARTIN JJ, BERSANO A, TOUZÉ E, TATLISUMAK T, **LYRER P**, BRANDT T; For the Cervical Artery Dissection and Ischemic Stroke Patients (CADISP) Study Group.  
Cervical artery dissection: Trauma and other potential mechanical trigger events.  
Neurology 2013; 80(21):1950-7. IF: 8.23

BRODERICK JP, PALESCH YY, DEMCHUK AM, YEATTS SD, KHATRI P, HILL MD, JAUCH EC, JOVIN TG, YAN B, SILVER FL, VON KUMMER R, MOLINA CA, DEMAERSCHALK BM, BUDZIK R, CLARK WM, ZAIDAT OO, MALISCH TW, GOYAL M, SCHONEWILLE WJ, MAZIGHI M, **ENGELTER S**, ANDERSON C, SPILKER J, CARROZZELLA J, RYCKBORST KJ, JANIS LS, MARTIN RH, FOSTER LD, TOMSICK TA; Interventional Management of Stroke (IMS) III Investigators.  
Endovascular therapy after intravenous t-PA versus t-PA alone for stroke.  
N Engl J Med. 2013; 368(10):893-903. IF: 51.66

DE STEFANO N, COMI G, **KAPPOS L**, FREEDMAN MS, POLMAN CH, UITDEHAAG BMJ, HENNESSY B, CASSET-SEMANAZ F, LEHR L, STUBINSKI B, JACK DL, BARKHOF F.  
Efficacy of subcutaneous interferon  $\beta$ -1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes.  
J Neurol Neurosurg Psychiatry. 2013 Nov 29. [Epub ahead of print] IF: 4.924

FILIPPI M, ROCCA MA, PAGANI E, DE STEFANO N, JEFFERY D, **KAPPOS L**, MONTALBAN X, BOYKO AN, COMI G; on behalf of the ALLEGRO Study Group.  
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.  
J Neurol Neurosurg Psychiatry. 2013 Sep 12. [Epub ahead of print] IF: 4.924

FISCHMANN A, **HAFNER P**, GLOOR M, SCHMID M, KLEIN A, POHLMAN U, WALTZ T, GONZALEZ R, HAAS T, BIERI O, **FISCHER D**  
Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophy.  
J Neurol. 2013; 260(4):969-74, IF: 3.578

FRANCIS G, **KAPPOS L**, O'CONNOR P, COLLINS W, TANG D, MERCIER F, COHEN JA.  
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy  
Multiple Sclerosis Journal 2013 August 15; [Epub ahead of print] IF: 4.472

FRIDGEN GJ, ASTON J, **GSCHWANDTNER U**, PFLUEGER M, **ZIMMERMANN R**, STUDERUS E, STIEGLITZ RD, RIECHER-RÖSSLER A.

Help-seeking and pathways to care in the early stages of psychosis.

Soc Psychiatry Psychiatr Epidemiol. 2013; 48(7):1033-43. IF: 2.861

GAIOTTINO J, NORNGREN N, DOBSON R, TOPPING J, NISSIM A, MALASPINA A, BESTWICK JP, MONSCH AU, REGENITER A, **LINDBERG RL**, **KAPPOS L**, LEPPERT D, PETZOLD A, GIOVANNONI G, **KUHLE J**

Increased neurofilament light chain blood levels in neurodegenerative neurological diseases

Plos One 2013, [epub ahead of print] IF: 3.73

GANTENBEIN AR, JAGGI C, STURZENEGGER M, **GOBBI C**, MERKI-FELD GS, EMMENEGGER MJ, TAUB E, SÁNDOR PS for the SHS Study Group

Awareness of headache and of National Headache Society activities among primary care physicians - a qualitative study

BMC research notes. 2013; 6:118 IF: 1.390

**GENSICKE H**, **SEIFFGE DJ**, POLASEK AE, **PETERS N**, **BONATI LH**, **LYRER P**, **ENGELTER S**.

Long-term outcome in stroke patients treated with IV thrombolysis.

Neurology 2013; 80(10):919-25. IF: 8.25

**GENSICKE H**, ZINKSTOK SM, ROOS YB, **SEIFFGE DJ**, RINGLEB P, ARTTO V, PUTAALA J, HAAPANIEMI E, LEYS D, BORDET R, MICHEL P, ODIER C, BERROUSCHOT J, ARNOLD M, HELDNER MR, ZINI A, BIGLIARDI G, PADJEN V, **PETERS N**, PEZZINI A, SCHINDLER C, SARIKAYA H, **BONATI LH**, TATLISUMAK T, **LYRER P**, NEDERKOORN PJ, **ENGELTER S**.

IV thrombolysis and renal function.

Neurology 2013; 81(20):1780-8. IF: 8.25

**GENSICKE H**, ZUMBRUNN T, JONGEN LM, NEDERKOORN PJ, MACDONALD S, GAINES PA, **LYRER P**, WETZEL SG, VAN DER LUGT A, MALI WP, BROWN MM, VAN DER WORP HB, **ENGELTER S**, **BONATI LH**.

Characteristics of ischemic brain lesions after stenting or endarterectomy for symptomatic carotid artery stenosis: Results from the international carotid stenting study-magnetic resonance imaging substudy.

Stroke 2013; 44(1):80-6. IF: 6.16

**GENSICKE H**, **FISCHER D**.

Response to Wakerley et al. Letter: Surgery itself does not trigger Guillain-Barré syndrome.

Eur J Neurol. 2013; 20(3):e41. IF 4.16

**GOBBI C**, MEIER DS, COTTON F, SINTZEL M, LEPPERT D, GUTTMANN CR, ZECCA C

Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial

BMC Neurol 2013; 13:101 IF: 2.564

**GOBBI C**, ZECCA C, LINNEBANK M, MÜLLER S, YOU X, MEIER R, BORTER E, TRABER M  
Swiss Analysis of Multiple Sclerosis (SAME): A Multicenter, Non-interventional, Retrospective Cohort Study of Disease-Modifying Therapies

Eur Neurol, 2013; 70(1):35-41 IF: 1.5

GROND-GINSBACH C, GIOSSI A, AKSAY SS, **ENGELTER S**, **LYRER P**, METSO TM, METSO AJ, TATLISUMAK T, DEBETTE S, LEYS D, THIJS V, BERSANO A, ABBOUD S, KLOSS M, LICHY C, GRAU A, PEZZINI A, TOUZÉ E; CADISP group.

Elevated peripheral leukocyte counts in acute cervical artery dissection.

Eur J Neurol. 2013; 20(10):1405-10. IF: 4.16

**HARDMEIER M, HATZ F, NAEGELIN Y, HIGHT D, SCHINDLER C, KAPPOS L, SEECK M, MICHEL CM, FUHR P.**

Improved Characterization of Visual Evoked Potentials in Multiple Sclerosis by Topographic Analysis.

Brain Topogr. 2013 Oct 2. [Epub ahead of print] IF: 3.671

HARRER A, TUMANI H, NIENDORF S, LAUDA F, GEIS C, WEISHAUP T A, KLEINSCHNITZ C, RAUER S, **KUHLE J**, STANGEL M, WEBER F, UHR M, LINNEBANK M, WILDEMANN B, JARIUS S, GUGER M, AYZENBERG I, CHAN A, ZETTL U, WIENDL H, PILZ G, HITZL W, WEBER J, KRAUS J

Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy

Multiple Sclerosis Journal 2013, 19(9):1209-1212 IF: 4.472

HARTUNG HP, STEINMAN L, GOODIN DS, COMI G, COOK S, FILIPPI M, O'CONNOR P, JEFFERY DR, **KAPPOS L**, AXTELL R, KNAPPERTZ V, BOGUMIL T, SCHWENKE S, CROZE E, SANDBRINK R, POHL C.

Interleukin 17F level and interferon  $\beta$  response in patients with multiple sclerosis.

JAMA Neurol. (Arch Neurol-Chicago) 2013; 70(8):1017-21. IF: 7.685

**HATZ F, BENZ N, HARDMEIER M, ZIMMERMANN R, RUEEGG S, SCHINDLER C, MISEREZ AR, GSCHWANDTNER U, MONSCH AU, FUHR P.**

Quantitative EEG and ApolipoproteinE-genotype improve classification of patients with suspected Alzheimer's disease.

Clin Neurophysiol. 2013; 124:2146-52 IF: 3.144

INKSTER B, STRIJBIJ EM, VOUNOU M, **KAPPOS L, RADUE EW**, MATTHEWS PM, UITDEHAAG BM, BARKHOF F, POLMAN CH, MONTANA G, GEURTS JJ.

Histone deacetylase gene variants predict brain volume changes in multiple sclerosis.

Neurobiol Aging. 2013; 34(1):238-47. IF: 6.166

IZQUIERDO G, O'CONNOR P, MONTALBAN X, VON ROSENSTIEL P, CREMER M, DE VERA A, SFIKAS N, FRANCIS G, **RADUE EW, KAPPOS L.**

Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.

Multiple Sclerosis Journal 2013 Nov 30. [Epub ahead of print] IF: 4.472

JAMES E, DOBSON R, **KUHLE J**, BAKER D, GIOVANNONI G, RAMAGOPALAN SV

The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis

Multiple Sclerosis Journal 2013, 19(12):1571-1579 IF: 4.472

**KAPPOS L, O'CONNOR PW, POLMAN CH, VERMERSCH P, WIENDL H, PACE A, ZHANG A, HOTERMANS C.**

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course.

J Neurol. 2013; 260(5):1388-95. IF: 3.578

KERASNOUDIS A, **DÉCARD BF**, GOLD R.

Clinical reasoning: a 48-year-old woman with progressive spastic-ataxic gait.

Neurology. 2013; 81(11):e75-80. IF: 8.249

KILLEEN T, **CZAPLINSKI A**, CESNULIS E

Extradural spinal cavernous malformation: a rare but important mimic.

British J Neurosurg. 2013 Sep 27 [Epub ahead of print] IF: 0.858

**KUHLE J, MALMESTRÖM C, AXELSSON M, PLATTNER K, YALDIZLI O, DERFUSS T, GIOVANNONI G, KAPPOS L, LYCKE J.**

Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.

Acta Neurol Scand. 2013; 128(6):e33-6. IF: 2.474

**KUHLE J**, PLATTNER K, BESTWICK JP, **LINDBERG RL**, RAMAGOPALAN S, NORGRÉN N, NISSIM A, MALASPINA A, LEPPERT D, GIOVANNONI G\*, **KAPPOS L\*** (\*equal contribution)  
A comparative study of CSF Neurofilament light and heavy chain protein in MS  
Multiple Sclerosis Journal 2013, 19(12):1597-1603 IF: 4.472

LAMPL C, NAGL S, ARNASON B, COMI G, O'CONNOR P, COOK S, JEFFERY D, **KAPPOS L**, FILIPPI M, BECKMANN K, BOGUMIL T, POHL C, SANDBRINK R, HARTUNG HP.  
Efficacy and safety of interferon beta-1b sc in older RRMS patients-a posthoc analysis of the BEYOND study.  
J Neurol. 2013; 260(7):1838-45. IF: 3.578

LÉGER JM, VIALA K, NICOLAS G, CRÉANGE A, VALLAT JM, POUGET J, CLAVELOU P, VIAL C, **STECK A**, MUSSET L, MARIN B; RIMAG STUDY GROUP (FRANCE AND SWITZERLAND). (**FUHR P** LISTED AS COINVESTIGATOR).  
Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy.  
Neurology. 2013; 80(24):2217-25. IF: 8.249

HEGEN H, MILLONIG A, BERTOLOTTO A, COMABELLA M, GIOVANNONI G, GUGER M, HOELZL M, KHALIL M, KILLESTEIN J, **LINDBERG R**, MALUCCHI S, **MEHLING M**, MONTALBAN X, POLMAN C, RUDZKI D, SCHAUTZER F, SELLEBJERG F, SØRENSEN P, DEISENHAMMER F.  
Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.  
Multiple Sclerosis Journal 2013 Sep 5. [Epub ahead of print] IF: 4.472

LUKAS C, SOMBEKKE MH, BELLENBERG B, HAHN HK, POPESCU V, **BENDFELDT K**, **RADUE EW**, GASS A, BORGWARDT SJ, **KAPPOS L**, **NAEGELIN Y**, KNOL DL, POLMAN CH, GEURTS JJ, BARKHOF F, VRENKEN H.  
Relevance of Spinal Cord Abnormalities to Clinical Disability in Multiple Sclerosis: MR Imaging Findings in a Large Cohort of Patients.  
Radiology. 2013; 269(2):542-52. IF: 6.339

MAYER MC, BREITHAUPT C, REINDL M, SCHANDA K, ROSTASY K, BERGER T, DALE RC, BRILOT F, OLSSON T, JENNE D, **PRÖBSTEL AK**, DORNMAIR K, WEKERLE H, HOHLFELD R, BANWELL B, BAR-OR A, MEINL E.  
Distinction of conformational epitopes on human myelin oligodendrocyte glycoprotein recognized by human antibodies.  
Journal of Immunology 2013; 191(7), 3594–3604. IF: 5.52

MEDLIN F, ZEKERIDOU A, **RENAUD S**, KUNTZER T.  
Favorable outcome of an acute complex regional pain syndrome with immunoglobulin infusions.  
Clin J Pain. 2013; 11:e33-4 IF: 2.552

**MEHLING M**, FRITZ S, **HAFNER P**, EICHIN D, YONEKAWA T, KLIMKAIT T, **LINDBERG RL**, **KAPPOS L**, HESS C.  
Preserved Antigen-Specific Immune Response in Patients with Multiple Sclerosis Responding to IFN $\beta$ -Therapy.  
PLoS One. 2013; 8(11):e78532. IF: 3.730

**MEHLING M**, BRINKMANN V, BURGNER AV, GUBSER P, LUSTER AD, **KAPPOS L**, HESS CH  
Homing-frequency of human T-cells inferred from peripheral blood depletion-kinetics after S1P-receptor blockade  
J Allergy Clin Immunol. 2013; 131(5):1440-3.e7 IF: 12.1

**NEDERKOORN PJ, ZINKSTOK SM, ENGELTER S.**

Response to Letter Regarding Article, "Safety of Thrombolysis in Stroke Mimics: Results From a Multicenter Cohort Study"

Stroke 2013; 44(9):e106. IF: 6.16

**NIAZI A, ANDELOVA M, SPRENGER T.**

Is the migrainous brain normal outside of acute attacks: lessons learned from psychophysical and functional neuroimaging studies.

Expert Rev Neurother 2013; 13:1061-7. IF: 2.955

**NÍ CHRÓINÍN D, ASPLUND K, ASBERG S, CALLALY E, CUADRADO-GODIA E, DÍEZ-TEJEDOR E, DI NAPOLI M, ENGELTER S, FURIE KL, GIANNOPOULOS S, GOTTO AM JR, HANNON N, JONSSON F, KAPRAL MK, MARTÍ-FÀBREGAS J, MARTÍNEZ-SÁNCHEZ P, MILIONIS HJ, MONTANER J, MUSCARI A, PIKIJA S, PROBSTFIELD J, ROST NS, THRIFT AG, VEMMOS K, KELLY PJ.**

Statin therapy and outcome after ischemic stroke: Systematic review and meta-analysis of observational studies and randomized trials.

Stroke 2013; 44(2):448-56 IF: 6.16

**O'CONNOR PW, LUBLIN FD, WOLINSKY JS, CONFAVREUX C, COMI G, FREEDMAN MS, OLSSON TP, MILLER AE, DIVE-POULETTY C, BÉGO-LE-BAGOUSSE G, KAPPOS L.**

Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use.

J Neurol. 2013; 260(10):2472-80. IF: 3.578

**O'FERRALL EK, GENDRON D, GUIOT MC, HALL J, SINNREICH M.**

Lower motor neuron syndrome due to cauda equina hypertrophy with onion bulbs.

Muscle Nerve. 2013; 48(2):301-5. IF: 2.314

**OZCELIK S, FRASER G, CASTETS P, SCHAEFFER V, SKACHOKOVA Z, BREU K, CLAVAGUERA F, SINNREICH M, KAPPOS L, GOEDERT M, TOLNAY M, WINKLER DT.**

Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice.

PLoS One. 2013; 8(5):e62459. IF: 3.73

**PANAITE PA, RENAUD S, KRAFTSIK R, STECK AJ, KUNTZER T.**

Impairment and disability in 20 CIDP patients according to disease activity status.

J Peripher Nerv Syst. 2013; 18(3):241-6. IF: 2.570

**PAPADOPOULOU A, MENEGOLA M, KUHLE J, RAMAGOPALAN SV, D'SOUZA M, SPRENGER T, RADUE EW, KAPPOS L, YALDIZLI O**

Lesion-to-ventricle distance and other risk factors for the persistence of newly formed black holes in relapsing-remitting multiple sclerosis.

Multiple Sclerosis Journal 2013, [epub ahead of print] IF: 4.472

**PAPADOPOULOU A, MÜLLER-LENKE N, NAEGELIN Y, KALT G, BENDFELDT K, KUSTER P, STOECKLIN M, GASS A, SPRENGER T, RADUE EW, KAPPOS L, PENNER IK**

Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis

Mult Scler J 2013;19:1290-1296. IF: 4.472

**PAPADOPOULOU A, AHLHELM F, ULMER S, KAPPOS L, SPRENGER T.**

Detection of CSF leaks by intrathecal contrast-enhanced MR myelography.

JAMA Neurol. 2013; 70(12):1576-7. IF: 7.685

**PENNER IK, HUBACHER M, RASENACK M, SPRENGER T, WEBER P, NAEGELIN Y.**

Utility of neuropsychological testing for guiding treatment decisions in a patient with pediatric multiple sclerosis.

Multiple Sclerosis Journal 2013;19:366-8. IF 4.472

**PEYER AK, ABICHT A, HEINIMANN K, SINNREICH M, FISCHER D.**

Quinine sulfate as a therapeutic option in a patient with slow channel congenital myasthenic syndrome.

Neuromuscul Disord. 2013; 23(7):571-4. IF: 3.464

**PEYER AK, KINTER J, HENCH J, FRANK S, FUHR P, THOMANN S, FISCHMANN A, KNEIFEL S, CAMAÑO P, MUNAIN AL, SINNREICH M, RENAUD S.**

Novel valosin containing protein mutation in a Swiss family with hereditary inclusion body myopathy and dementia.

Neuromuscul Disord. 2013; 23(2):149-54. IF: 3.464

**PREININGEROVA JL, BAUMHACKL U, CSEpany T, CZAPLINSKI A, DEISENHAMMER F, DERFUSS T, FABJAN TH, FAZEKAS F, FUCHS S, HAVRDOVA E, LEDINEK AH, ILLES Z, JAZBEC SS, KLIMOVA E, KOMOLY S, KURCA E, LINNEBANK M, LISY L, MARES J, PROCHAZKOVA L, CSILLA R, SZILASIOVA J, STOURAC P, TALAB R, TURCANI P, VACHOVA M, VECSEI L, VODUSEK D, ZAPLETALOVA O, BERGER T.**

Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS).

CNS Neurosci Ther. 2013; 19(5):302-6. IF: 4,46

**PUENTES F, TOPPING J, KUHLE J, VAN DER STAR BJ, DOUURI A, GIOVANNONI G, BAKER D, AMOR S, MALASPINA A**

Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis.

Journal of Neurology Neurosurgery and Psychiatry 2013, [epub ahead of print] IF: 4.924

**RADUE EW, BENDFELDT K, MÜLLER-LENKE N, MAGON S, SPRENGER T.**

Brain atrophy: an in vivo measure of disease activity in multiple sclerosis.

Swiss Med Wkly. 2013 21;143:w13887. IF: 1.821

**RAMIEN C, PACHNIO A, SISAY S, BEGUM J, LEESE A, DISANTO G, KUHLE J, GIOVANNONI G, RICKINSON A, RAMAGOPALAN SV, MOSS P, MEIER UC**

Hypovitaminosis-D and EBV: no interdependence between two MS risk factors in a healthy young UK autumn cohort.

Multiple Sclerosis Journal 2013, [epub ahead of print] IF: 4.472

**RANTNER B, GOEBEL G, BONATI LH, RINGLEB PA, MAS JL, FRAEDRICH G.**

The risk of carotid artery stenting compared with carotid endarterectomy is greatest in patients treated within 7 days of symptoms.

J Vasc Surg 2013; 57(3):619-26. IF: 2.88

**RICKLIN M, LORSCHIEDER J, WASCHBISCH A, PAROZ C, MEHTA SK, PIERSON DL, KUHLE J, FISCHER-BARNICOL B, SPRENGER T, LINDBERG R, KAPPOS L, DERFUSS T.**

T cell response against varicella zoster virus in Fingolimod-treated MS patients.

Neurology 2013; 81(2):174-81. IF: 8.249

**RIECHER-RÖSSLER A, ASTON J, BORGWARDT S, BUGRA H, FUHR P, GSCHWANDTNER U, KOUTSOULERIS N, PFLUEGER M, TAMAGNI C, RADÜ EW, RAPP C, SMIESKOVA R, STUDERUS E, WALTER A, ZIMMERMANN R.**

Prediction of psychosis by stepwise multilevel assessment--the Basel FePsy (Early Recognition of Psychosis)-Project.

Fortschr Neurol Psyc, 2013; 81(5):265-75 IF: 0.851

**ROPELE S, WATTJES MP, LANGKAMMER C, KILSDONK ID, DE GRAAF WL, FREDERIKSEN JL, FUGLØ D, CICCARELLI O, ENZINGER C, ROCCA MM, SPRENGER T, AMANN M, FILIPPI M, ROVIRA A, MILLER DH, BARKHOF F, FAZEKAS F.**

Multicenter R2\* mapping in the healthy brain.

Magn Reson Med. 2013 May 8. [Epub ahead of print] IF: 3.267



ROSTAMZADEH A, ZUMBRUNN T, JONGEN LM, NEDERKOORN PJ, MACDONALD S, **LYRER P**, KAPPELLE LJ, MALI WP, BROWN MM, VAN DER WORP HB, **ENGELTER S**, **BONATI LH**; on behalf of the ICSS-MRI Substudy Investigators  
Predictors of acute and persisting ischemic brain lesions in patients randomized to carotid stenting or endarterectomy.  
Stroke. 2013 Dec 24. [Epub ahead of print] IF: 6.16

SCHEITZ JF\*, **SEIFFGE DJ\***, TÛTÛNCÛ S, **GENSICKE H**, AUDEBERT HJ, **BONATI LH**, FIEBACH JB, **TRÄNKA C**, **LYRER P**, ENDRES M, **ENGELTER S\***, NOLTE CH\* (\*Equal contribution)  
Dose-related effects of statins on symptomatic intracerebral hemorrhage and outcome after thrombolysis for ischemic stroke.  
Stroke. 2013 Dec 24. [Epub ahead of print] IF: 6.16

**SCHLAEGER R**, **D'SOUZA M**, SCHINDLER C, GRIZE L, **KAPPOS L**, **FUHR P**.  
Electrophysiological markers and predictors of the disease course in primary progressive multiple sclerosis.  
Multiple Sclerosis Journal 2013 Jun 11. [Epub ahead of print] IF: 4.472

SCHULZE C, **ZIMMERMANN R**, **GSCHWANDTNER U**, PFLUEGER MO, RAPP C, STUDERUS E, RIECHER-RÖSSLER A.  
Can cognitive deficits facilitate differential diagnosis between at-risk mental state for psychosis and depressive disorders?  
Early Interv Psychia, 2013; 7(4):381-90. IF: 1.653

SEIFERT C, CHAKRAVARTY MM, **SPRENGER T**.  
The complexities of pain after stroke- a review with a focus on central post-stroke pain.  
Panminerva Med, 2013; 55:1-10. IF: 0.982

**SEIFFGE DJ**, KARAGIANNIS A, STRBIAN D, **GENSICKE H**, **PETERS N**, **BONATI LH**, KOTISAARI K, LEPPÄ M, **KEJDA-SCHARLER J**, **TRÄNKA C**, GINSBACH P, TATLISUMAK T, **LYRER P**, **ENGELTER S**.  
Simple variables predict miserable outcome after intravenous thrombolysis.  
Eur J Neurol. 2013 Sep 7. [Epub ahead of print] IF: 4.162

**SEIFFGE D**; **TRÄNKA C**; **GENSICKE H**; TSAKIRIS D; **BONATI L**; **PETERS N**; **LYRER P**; **ENGELTER S**.  
IV-thrombolysis in stroke patients receiving rivaroxaban.  
Eur J Neurol. 2013 [Epub 15.12.13] IF: 4.16

SELMAJ K, LI DK, HARTUNG HP, HEMMER B, **KAPPOS L**, FREEDMAN MS, STÛVE O, RIECKMANN P, MONTALBAN X, ZIEMSEN T, AUBERSON LZ, POHLMANN H, MERCIER F, DAHLKE F, WALLSTRÖM E.  
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.  
Lancet Neurol. 2013;12(8):756-67. Erratum in: Lancet Neurol. 2013;12(9):846. IF: 23.917

**SPRENGER T**, **MAGON S**.  
Can functional magnetic resonance imaging at rest shed light on the pathophysiology of migraine?  
Headache 2013; 53:723-725. IF: 2.937

**SPRENGER T**, SEIFERT CL.  
Coma after greater occipital nerve blockade in a patient with previous posterior fossa surgery.  
Headache 2013; 53:548-550. IF: 2.937

**SPRENGER T**, SUPRONSINCHAI W, GOADSBY PJ.

New onset Migraine with aura after treatment initiation with Ivabradine.

J Headache Pain 2013; 14(1):45. IF: 2.779

STANKEWITZ A, VALET M, SCHULZ E, WÖLLER A, **SPRENGER T**, VOGEL D, ZIMMER C, MÜHLAU M, TÖLLE TR.

Pain sensitizers exhibit grey matter changes after repetitive pain exposure - a longitudinal VBM study.

Pain 2013; 154(9):1732-7. IF: 5.644

**STECK A**, STRUHAL W, SERGAY SM, GRISOLD W; Education Committee World Federation of Neurology.

The global perspective on neurology training: the World Federation of Neurology survey.

J Neurol Sci. 2013; 334(1-2):30-47. IF: 2.243

**STECK A**, YUKI N, GRAUS F.

Antibody testing in peripheral nerve disorders.

Handb Clin Neurol. 2013;115:189-212.

STRBIAN D, **SEIFFGE DJ**, BREUER L, NUMMINEN H, MICHEL P, MERETOJA A, COOTE S, BORDET R, OBACH V, WEDER B, JUNG S, CASO V, CURTZE S, OLLIKAINEN J, **LYRER P**, ESKANDARI A, MATTLE HP, CHAMORRO A, LEYS D, BLADIN C, DAVIS SM, KÖHRMANN M, **ENGELTER S**, TATLISUMAK T.

Validation of the DRAGON Score in 12 Stroke Centers in Anterior and Posterior Circulation.

Stroke. 2013; 44(10):2718-21 IF: 6.16

STRBIAN D, MICHEL P, RINGLEB P, NUMMINEN H, BREUER L, BODENANT M, **SEIFFGE DJ**, JUNG S, OBACH V, WEDER B, TIAINEN M, ESKANDARI A, GUMBINGER C, **GENSICKE H**, CHAMORRO A, MATTLE HP, **ENGELTER S**, LEYS D, KÖHRMANN M, PARKKILA AK, HACKE W, TATLISUMAK T.

Relationship between Onset-to-Door time and Door-to-Thrombolysis time: A pooled analysis of 10 dedicated stroke centers.

Stroke. 2013 Jul 25. [Epub ahead of print] IF: 6.16

STRBIAN D, RINGLEB P, MICHEL P, BREUER L, OLLIKAINEN J, MURAO K, **SEIFFGE DJ**, JUNG S, OBACH V, WEDER B, ESKANDARI A, GENSICKE H, CHAMORRO A, MATTLE HP, **ENGELTER S**, LEYS D, NUMMINEN H, KÖHRMANN M, HACKE W, TATLISUMAK T.

Ultra-Early Intravenous Stroke Thrombolysis: Do All Patients Benefit Similarly?

Stroke. 2013 Aug 22. [Epub ahead of print] IF: 6.16

STRIJBIS EM, INKSTER B, VOUNOU M, **NAEGELIN Y**, **KAPPOS L**, **RADUE EW**, MATTHEWS PM, UITDEHAAG BM, BARKHOF F, POLMAN CH, MONTANA G, GEURTS JJ.

Glutamate gene polymorphisms predict brain volumes in multiple sclerosis.

Multiple Sclerosis Journal 2013; 19(3):281-8. IF: 4.472

**SUTTER R**, MARSCH S, **FUHR P**, **RÜEGG ST**.

Mortality and recovery from refractory status epilepticus in the intensive care unit: A 7-year observational study.

Epilepsia 2013; 54: 502-11. IF: 3.909

**SUTTER R**, GRIZE L, **FUHR P**, **RÜEGG ST**, MARSCH S.

Acute-phase proteins and mortality in status epilepticus: A 5-year observational cohort study.

Crit Care Med. 2013; 41(6):1526-1533. IF: 6.124

SUTTER R, KAPLAN PW, **RÜEGG ST.**

Independent external validation of the Status Epilepticus Severity Score (STESS): Results from a six-year cohort study.

Crit Care Med 2013; 41: 1-6. IF: 6.124

**SUTTER R**, MARSCH S, **FUHR P**, KAPLAN P, **RÜEGG ST.**

Anesthetic drugs in Status Epilepticus - risk or rescue? A six-year cohort study.

Neurology. 2013 Dec 6. [Epub ahead of print] IF: 8.249

SUTTER R, MARSCH S, **RÜEGG ST.**

Safety and efficacy of intravenous lacosamide for adjunctive treatment of refractory status epilepticus: a comparative cohort study.

CNS Drugs 2013; 27: 321-9. IF 4.826

TAMAGNI C, STUDERUS E, **GSCHWANDTNER U**, ASTON J, BORGWARDT S, RIECHER-RÖSSLER A.

Are neurological soft signs pre-existing markers in individuals with an at-risk mental state for psychosis?

Psychiat Res, 2013; 210(2):427-31. IF: 2.456

TOUZE E, TRINQUART L, FELGUEIRAS R, RERKASEM K, **BONATI LH**, MELIKSETYAN G, RINGLEB PA, MAS JL, BROWN MM, ROTHWELL PM.

A clinical rule (sex, contralateral occlusion, age, and restenosis) to select patients for stenting versus carotid endarterectomy: systematic review of observational studies with validation in randomized trials.

Stroke 2013; 44(12):3394-400. IF: 6.16

VAN DER WORP HB, **BONATI LH**, BROWN MM.

Carotid stenosis.

N Engl J Med 2013; 369(24):2359. IF: 51.66

VERMERSCH P, CZLONKOWSKA A, GRIMALDI LM, CONFAVREUX C, COMI G, **KAPPOS L**, OLSSON TP, BENAMOR M, BAUER D, TRUFFINET P, CHURCH M, MILLER AE, WOLINSKY JS, FREEDMAN MS, O'CONNOR P; for the TENERE Trial Group.

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.

Multiple Sclerosis Journal 2013 Nov 21. [Epub ahead of print] IF: 4.472

VIANA M, **SPRENGER T**, **ANDELOVA M**, GOADSBY PJ.

The typical duration of migraine aura: a systematic review.

Cephalalgia 2013; 33:483-90. IF: 3.485

WAGNER KJ, SCHULZ CM, **SPRENGER T**, PIEPER T, HEUSER F, HOHMANN CP, WERMKE M, MARTIN J, DRZEZGA A.

Comparing Propofol versus Sevoflurane anesthesia for epileptogenic focus detection during Positron Emission Tomography in pediatric patients.

Minerva Anesthesiologica 2013; 79(11):1264-8. IF: 2.818

WASCHBISCH A, ATIYA M, SCHAUB C, **DERFUSS T**, SCHWAB S, LEE DH, MÜLLER M, LINKER RA.

Aquaporin-4 antibody negative recurrent isolated optic neuritis: clinical evidence for disease heterogeneity.

J Neurol Sci. 2013; 331(1-2):72-5. IF: 2.24

**WEIER K, NAEGELIN Y, AMANN M, MAGON S, MUELLER-LENKE N, RADUE EW, KAPPOS L, STIPPICH C, GASS A, SPRENGER T.**

Six year follow-up of a case-series with non-communicating syringomyelia in Multiple Sclerosis.  
Eur J Neurol 2013; 20:578-83. IF: 4.162

**WOLINSKY JS, NARAYANA PA, NELSON F, DATTA S, O'CONNOR P, CONFAVREUX C, COMI G, KAPPOS L, OLSSON TP, TRUFFINET P, WANG L, MILLER A, FREEDMAN MS; FOR THE TERIFLUNOMIDE MULTIPLE SCLEROSIS ORAL (TEMSO) TRIAL GROUP.**

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.  
Multiple Sclerosis Journal 2013; 19(10):1310-9. IF: 4.472

**YALDIZLI O, PENNER IK, FRONTZEK K, NAEGELIN Y, AMANN M, PAPADOPOULOU A, SPRENGER T, KUHLE J, CALABRESE P, RADU EW, KAPPOS L, GASS A**

The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients.

Multiple Sclerosis Journal 2013, [epub ahead of print] IF: 4.472

**YESILOT BARLAS N, PUTAALA J, WAJE-ANDREASSEN U, VASSILOPOULOU S, NARDI K, ODIER C, HOFGART G, ENGELTER S, BUROW A, MIHALKA L, KLOSS M, FERRARI J, LEMMENS R, COBAN O, HAAPANIEMI E, MAAIJWEE N, RUTTEN-JACOBS L, BERSANO A, CEREDA C, BARON P, BORELLINI L, VALCARENGHI C, THOMASSEN L, GRAU AJ, PALM F, URBANEK C, TUNCAY R, DURUKAN TOLVANEN A, VAN DIJK EJ, DE LEEUW FE, THIJS V, GREISENEGGER S, VEMMOS K, LICHY C, BERECZKI D, CSIBA L, MICHEL P, LEYS D, SPENGOS K, NAESS H, TATLISUMAK T, BAHAR SZ.**

Etiology of first-ever ischaemic stroke in European young adults: the 15 cities young stroke study.  
Eur J Neurol. 2013; 20(11):1431-9. IF: 4.16

**ZIEREN N, DUERING M, PETERS N, REYES S, JOUVENT E, HERVÉ D, GSCHWENDTNER A, MEWALD Y, OPHERK C, CHABRIAT H, DICHGANS M.**

Education modifies the relation of vascular pathology to cognitive function: cognitive reserve in cerebral autosomal dominant arteriopathy with subcortical infarcts and leuko-encephalopathy.

Neurobiol Aging. 2013; 34:400-7. IF: 6.166

**ZINKSTOK SM, ENGELTER S, GENSICKE H, LYRER P, RINGLEB PA, ARTTO V, PUTAALA J, HAAPANIEMI E, TATLISUMAK T, CHEN Y, LEYS D, SARIKAYA H, MICHEL P, ODIER C, BERROUSCHOT J, ARNOLD M, HELDNER MR, ZINI A, FIORAVANTI V, PADJEN V, BESLAC-BUMBASIREVIC L, PEZZINI A, ROOS YB, NEDERKOORN PJ.**

Safety of thrombolysis in stroke mimics: Results from a multicenter cohort study.

Stroke. 2013; 44(4):1080-4. IF: 6.16

## **B - BUCHBEITRÄGE, EDITORIALS & REVIEWS**

(Alphabetisch nach Erstautor sortiert)

**AXER H, M. AXER M, GRIMM A**

Elektrophysiologische Diagnostik der Critical Illness Polyneuropathie und Critical Illness Myopathie  
Das Neurophysiologie Labor 2013; 35 (1): 18-33

**BONATI LH, ECKSTEIN HH.**

Interventions for carotid stenosis: new evidence.  
Eur J Vasc Endovasc Surg 2013; 46(5): 508-9. IF: 2.82

**CZAPLINSKI A**

Multiple Sklerose: wie Sie Mimicks auf die Spuren kommen  
Info Neurologie und Psychiatrie 2013; 11(6)

**CZAPLINSKI A**

Radikulopathie diagnostizieren und therapieren  
Info Neurologie und Psychiatrie 2013; 11(2): 12

**CZAPLINSKI A**

Evaluation der Polyneuropathien und Therapieoptionen bei häufigen Formen  
Schweiz Med Forum 2013; 13(24): 476-482.

**CZAPLINSKI A**

Warum ein Karpaltunnelsyndrom keine Banalität ist.  
Leading opinions in Neurologie und Psychiatrie 2013; 12; 33.

**DERFUSS T, KUHLE J, LINDBERG R, KAPPOS L.**

Natalizumab therapy for multiple sclerosis.  
Semin Neurol. 2013; 33(1):26-36. IF: 1.509

**DERFUSS T, KAPPOS L.**

Predicting PML in natalizumab-treated patients: can we do better?  
J Neurol Neurosurg Psychiatry. 2013; 84(11):1182-3. IF: 4.924

**ENGELTER S**

Restless legs Syndrom.  
Der informierte Arzt 2013(9): 44-46

**FUHR P, GSCHWANDTNER U, BRUNNSCHWEILER H, TAUB E.**

Practical aspects of the treatment of Parkinson's disease.  
Praxis. 2013; 102(16):981-5.

**GRIMM A, WITTE OW, AXER H**

Muskelultraschall in der neurologischen Diagnostik – ein Überblick  
Das Neurophysiologie Labor 2013; 35; 47-60

**GRIMM A, TESCHNER U, PORZELIUS C, LUDEWIG K, ZIELSKE J, WITTE OW, BRUNKHORST FM, AXER H**

Muscle ultrasound for early assessment of critical illness neuromyopathy in severe sepsis  
Crit Care. 2013 Oct 7; 17(5):R227. [Epub ahead of print] IF: 4.72

**GRIMM A, PRELL T, WITTE OW, AXER H, GROSSKREUTZ J**

Sonography of Muscles - A Useful Tool in the Diagnosis of Amyotrophic Lateral Sclerosis  
Klin Neurophysiol 2013; 44(02): 140-144 IF: 0.327

**GRIMM A, AXER H**  
Muskelultraschall und Critical Illness Polyneuropathie.  
Intensiv-News 2013; 4; 34-36.

**GRIMM A, BRUNKHORST FM, AXER H**  
Sepsis-induzierte CIP und CIM: Neuromuskuläre Schwäche.  
NeuroTransmitter 2013; 24:36-43.

**MEHLING M, KAPPOS L**  
Fingolimod  
Schweiz Med Forum 2013(11): 237-238

**PAPADOPOULOU A, D'SOUZA M, KAPPOS L**  
Dimethylfumarat (BG-12)  
Schweiz Med Forum 2013; 13: 761-762

**RADUE EW, BENDFELDT K, SPRENGER T.**  
Measurement of cerebral atrophy in multiple sclerosis.  
In: Weinstock-Guttman B, Ramanathan M, Zivadinov R (Hrsg.): Personalized management of multiple sclerosis (Ebook). Future Science Group 2013: p.134-147.

**RÜEGG S**  
Warum hören epileptische Anfälle auf? Nicht-medikamentöse Mechanismen.  
Epileptologie 2013; 30: 218-231.

**RÜEGG S**  
Symptomatische epileptische Anfälle – womit behandeln?  
Epileptologie 2013; 30: 243-260.

**SEIFFGE D, ENGELTER S, LYRER P**  
Neue Antikoagulantien in der Neurologie - Wann und für wen?  
Psychiatrie & Neurologie 2013; (4): 38-44

**SEIFFGE D, LYRER P.**  
Auskultation der Karotiden – Bedeutung eines Geräusches  
Therapeutische Umschau 2013; 70(5): 275-277

**SCHLAEGER R, HARDMEIER M, FUHR P**  
Superficial brain stimulation in multiple sclerosis.  
Handb Clin Neurol. 2013;116: 577-84.

STANKEWITZ A, **SPRENGER T**, SCHULZ E. TÖLLE TR.  
Positron emission tomography for assessing neuronal activity and metabolism in acute and chronic pain.  
In: Arendt-Nielsen I, Handwerker HH (Hrsg.): Pain Models: Translational Relevance and Applications, IASP Press, Washington. 2013: p.359-372.

SUTER M, **SPRENGER T**, TAUB E, BESSON M.  
Nouveaux concepts dans la physiopathologie, le diagnostic et le traitement de la douleur neuropathique.  
Rev Med Suisse 2013; 9(392):1346, 1348-50

SUTTER R, KAPLAN PW, **RÜEGG S.**  
Predicting outcome in adults with status epilepticus: What counts, and what doesn't.  
Nat Rev Neurol 2013; 9: 525-534. IF: 15.518

**SUTTER R, RÜEGG S.**

Prognosestellung bei erwachsenen Patienten mit Status Epilepticus.  
Z Epileptol 2013; 26: 79-84.

TEUNISSEN C, MENGE T, ALTINTAS A, ALVAREZ-CERMENO JC, BERTOLOTTO A, BERVEN FS, BRUNDIN L, COMABELLA M, DEGN M, DEISENHAMMER F, FAZEKAS F, FRANCIOTTA D, FREDERIKSEN JL, GALIMBERTI D, GNANAPAVAN S, HEGEN H, HEMMER B, HINTZEN R, HUGHES S, IACOBAEUS E, KROKSVEEN AC, **KUHLE J**, RICHERT J, TUMANI H, VILLAR LM, DRULOVIC J, DUJMOVIC I, KHALIL M, BARTOS A

Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis.

Multiple Sclerosis Journal 2013; 19(13):1802-9. IF: 4.472

**VANEY C, DERFUSS T.**

What's new in multiple sclerosis therapy?  
Rev Med Suisse 2013; 9(371): 285-7

VRENKEN H, JENKINSON M, HORSFIELD MA, BATTAGLINI M, VAN SCHIJNDEL RA, ROSTRUP E, GEURTS JJ, FISHER E, ZIJDENBOS A, ASHBURNER J, MILLER DH, FILIPPI M, FAZEKAS F, ROVARIS M, ROVIRA A, BARKHOF F, DE STEFANO N; MAGNIMS Study Group\*.  
(\***KAPPOS L** member of the MAGNIMS Study Group)

Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis.

J Neurol. 2013; 260(10):2458-71. IF: 3.578

**WATTJES MP, FISCHER D** (Hrsg.)

Neuromuscular imaging  
Springer, New York, 2013

**YALDIZLI Ö, KUHLE J, DERFUSS T, SPRENGER T, KAPPOS L**

Neurologist-in-training: Multiple sclerosis

Schweizer Archiv für Neurologie und Psychiatrie 2013; 164(01):37-40